Skip to main content
TanyaKanker

Advanced treatment

Targeted Therapy

Drugs that act on a specific molecular marker in cancer cells, chosen from biomarker test results.

Upload ReportClinical trials in this category
Diagram abstrak terapi target: molekul mengikat satu reseptor pada membran sel
Terapi targetDraft, not yet medically reviewed

Not a diagnosis and not final medical advice. Must be reviewed by a doctor.

What is it?

Targeted therapy relies on biomarkers, so molecular testing is an important part of planning.

Some drugs are given orally and some through infusion.

Progression after targeted therapy remains possible so tissue reexamination is often considered.

The drugs inhibit specific signaling pathways that drive cancer cell growth, rather than attacking all rapidly dividing cells.
How Targeted Therapy

How it works

The drugs inhibit specific signaling pathways that drive cancer cell growth, rather than attacking all rapidly dividing cells.

Position in the treatment pathway: Generally considered when actionable markers are found, often in advanced or relapsing disease.

Diagram abstrak terapi target: molekul mengikat satu reseptor pada membran sel

What is the process like?

  1. Preparation 1

    Make sure the molecular examination report is available and completely legible.

  2. Preparation 2

    Check for interactions with other drugs you are taking.

  3. Monitoring

    Periodic imaging to assess response.

All preparation

  • Make sure the molecular examination report is available and completely legible.
  • Check for interactions with other drugs you are taking.

All monitoring

  • Periodic imaging to assess response.
  • Laboratory tests to monitor side effects.

Risks and points to watch

Side-effect notes, not a complete list

This list covers categories commonly discussed. Individual risk is always assessed by the treating team.
  • Side effects vary by target and may differ from classic chemotherapy.
  • Complaints such as rashes, diarrhea, or certain organ disorders need to be reported.

What needs to be checked?

Cost and access

Cost figures depend heavily on location, facility and payer. We do not show estimated figures on this page; what can be prepared first are the questions.

  • Osimertinib

    Third generation EGFR tyrosine kinase inhibitor

    • Availability may vary between health facilities and changes over time.
    • Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
    • Prices are not listed because they cannot be verified responsibly.

  • Alectinib

    Second generation ALK inhibitors

    • Availability may vary between health facilities and changes over time.
    • Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
    • Prices are not listed because they cannot be verified responsibly.

  • Lorlatinib

    Third generation ALK/ROS1 inhibitor

    • Availability may vary between health facilities and changes over time.
    • Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
    • Prices are not listed because they cannot be verified responsibly.

  • Sotorasib

    KRAS G12C inhibitor

    • Availability may vary between health facilities and changes over time.
    • Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
    • Prices are not listed because they cannot be verified responsibly.

  • Tepotinib

    Selective MET inhibitor

    • Availability may vary between health facilities and changes over time.
    • Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
    • Prices are not listed because they cannot be verified responsibly.

  • Selpercatinib

    Selective RET inhibitor

    • Availability may vary between health facilities and changes over time.
    • Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
    • Prices are not listed because they cannot be verified responsibly.

  • Trastuzumab deruxtecan

    Anti-HER2 antibody-drug conjugate

    • Availability may vary between health facilities and changes over time.
    • Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
    • Prices are not listed because they cannot be verified responsibly.

  • Zolbetuximab

    Anti-CLDN18.2 monoclonal antibody

    • Availability may vary between health facilities and changes over time.
    • Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
    • Prices are not listed because they cannot be verified responsibly.

  • Dabrafenib

    BRAF inhibitors

    • Availability may vary between health facilities and changes over time.
    • Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
    • Prices are not listed because they cannot be verified responsibly.

  • Trametinib

    MEK inhibitor

    • Availability may vary between health facilities and changes over time.
    • Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
    • Prices are not listed because they cannot be verified responsibly.
Treatment cost toolCost information centreCara meminta perkiraan biaya pengobatan: dokumen dan informasi yang diperlukan

Providers and clinical trials

Access status not yet verified

Studies are filtered from the public registry. Site readiness and international patient acceptance still need confirmation before any travel is planned.
View all studies in this categoryExplore hospitals

Questions for the doctor

  • Which marker is the basis for choosing this category of drugs?
  • What will be done if progression occurs?
  • Is it necessary to take a new tissue sample before starting?

Sources

Is Targeted Therapy relevant for my case?

Ask for an initial review. We will explain which documents and markers need to be completed before discussion with a doctor.

Upload ReportRequest a second opinion

  1. Upload reports

    Photos or PDFs of pathology, biomarkers, imaging and treatment history.

  2. Case structured

    Documents are turned into a structured case summary.

  3. Navigator review

    A human navigator checks completeness before anything is shared.

  4. Provider review

    With your consent, the case is discussed with providers for assessment and a written quote.

Is Targeted Therapy relevant for my case?

Ask for an initial review. We will explain which documents and markers need to be completed before discussion with a doctor.

Consult via WhatsAppUpload Medical Reports

After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.

Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.

Next steps

These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.

Next to learn

To check

What you can do

  • Upload medical reports

    Build a case summary in twelve steps

    Reason: Often the most useful next step after reading this page

  • Request a second opinion

    Review of the treatment plan

    Reason: Relevant when a treatment plan is being considered

  • Consult a navigator

    A request is recorded with this page context

    Reason: For asking the next step directly

Recently updated

Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.

Upload ReportSecond Opinion

Prepare for your next consultation

Use the free six-question tool to prepare questions for your doctor.

Start free · 6 questionsContact a navigatorSaved pages